Dr. Rastetter has been a director and has served as Chairman of the Board since May 2009, and from May 2009 to November 2010 he was our Acting Chief Executive Officer. He is a Co-Founder of Receptos, Inc. Dr. Rastetter served as a Partner at the venture capital firm of Venrock Associates from 2006 to February 2013. Prior to his tenure with us and Venrock, Dr. Rastetter was Executive Chairman of Biogen Idec, from the merger of the two companies (Biogen and Idec Pharmaceuticals) in 2003 through the end of 2005. He joined Idec Pharmaceuticals at its founding in 1986 and served as Chairman and CEO. Prior to Idec, he was Director of Corporate Ventures at Genentech, Inc. and served as well in a scientific capacity at Genentech. Dr. Rastetter also serves as the Chairman of Illumina, Inc., Neurocrine Biosciences, Inc. and Fate Therapeutics Inc. and as a director of Regulus Therapeutics, Inc. Dr. Rastetter held various faculty positions at the Massachusetts Institute of Technology and Harvard University and is an Alfred P. Sloan Fellow. Dr. Rastetter holds a B.S. in Chemistry from the Massachusetts Institute of Technology and received his M.A. and Ph.D. in Chemistry from Harvard University.
Managing Director and Partner of ARCH Venture Partners
Ms. Burow has served as one of our directors since February 2010 and is one of our Co‑Founders. She is also a Managing Director with ARCH Venture Partners, joining the firm in 2002. Ms. Burow is a co-founder and director of Sapphire Energy and also a director of Lycera and Kilimanjaro Energy, among other companies. Prior to ARCH, Ms. Burow was an Associate with the Novartis BioVenture Fund in San Diego where she was involved in numerous investments in the life science sector. As an early employee at the Genomics Institute of the Novartis Research Foundation (GNF), she directed Chemistry Operations and was active in Business Development where she helped create numerous companies as spin outs from GNF. Ms. Burow holds a M.B.A. from the University of Chicago, a M.A. in Chemistry from Columbia University and a B.S. in Chemistry from the University of California, Berkeley.
Dr. Cole has served as one of our directors since November 2009. Dr. Cole is also a General Partner of Flagship Ventures, having joined Flagship in 2001. He focuses on life science investments. He currently serves on the Boards of Directors of Agios, Avedro, Inc., Concert Pharmaceuticals Inc., Ensemble Therapeutics Corporation, Quanterix Corporation, Selecta Biosciences, Inc., Permeon Biologics, Syros Pharmaceuticals and Tetraphase Pharmaceuticals. He formerly served on the Board of Directors of CombinatoRx, Seventh Sense Biosystems, Resolvyx Pharmaceuticals, CGI Pharmaceuticals, Moderna and Morphotek (acquired by Eisai, Inc.). He is a member of the Scientific Advisory Boards of the Spinal Muscular Atrophy Foundation, the Massachusetts Life Sciences Center, the Harvard Technology Development Accelerator Fund, and the Genetics Advisory Council of the Harvard‑Partners Center for Genetics and Genomics. He also serves on the Board of Directors of the Spinal Muscular Atrophy Foundation. Dr. Cole joined Flagship from Vertex Pharmaceuticals, where he served as Program Executive and led a multidisciplinary program in tissue protection and repair and oversaw an international research collaboration. Previous to that, he was Medical Director at Cytotherapeutics in charge of various research and clinical activities related to the company’s cell-based therapeutic technologies. In 1992, Dr. Cole was appointed Instructor in Neurology at Harvard Medical School and an Assistant in Neurology at the Massachusetts General Hospital. Dr. Cole earned an A.B. magna cum laude with High Distinction in English from Dartmouth College and an M.D. from the University of Pennsylvania School of Medicine. He obtained post-graduate training in medicine at the Johns Hopkins Hospital in Baltimore, Maryland and in neurology at the Massachusetts General Hospital in Boston.
Mr. Torres has served as one of our directors since November 2009. He has been a Managing Director of Lilly Ventures Fund I, LLC, a venture capital fund since 2009. From 2006 to 2009, he was a Managing Director of Lilly Ventures while Lilly Ventures was a subsidiary of Eli Lilly and Company. Since co-founding Lilly Ventures, he has led the investments in, and previously served on the boards of, Serenex (acquired by Pfizer), Conforma Therapeutics (acquired by Biogen Idec) and Cabrellis Pharmaceuticals (acquired by Pharmion Corporation). Mr. Torres currently sits on the boards of Cylene Pharmaceuticals, Trinity Biosystems GlobeImmune, and Viamet Pharmaceuticals as well as various non-profit institutions. Prior to joining Lilly Ventures, he had a diverse set of experiences throughout the domestic and international pharmaceutical businesses including operational finance, planning, M&A, business development and global marketing roles. Mr. Torres received a B.A. from Creighton University and a M.B.A. from the University of Michigan Business School, where he was a Consortium Fellow.
Executive Vice President and Chief Financial Officer at Clovis Oncology
Erle T. Mast has been a director of the Company since July 2013 and also serves as a member of the Company's Audit Committee. Mr. Mast is a co-founder of Clovis Oncology, Inc. and has served as its Executive Vice President and Chief Financial Officer since 2009. Previously, Mr. Mast served in the same role at Pharmion Corporation, beginning in 2002. From 1997 through 2002, Mr. Mast worked for Dura Pharmaceuticals, Inc. and its successor, Elan Corporation. From 2000 to 2002, he served as Chief Financial Officer for the Global Biopharmaceuticals business unit for Elan. From 1997 to 2000, Mr. Mast served as Vice President of Finance for Dura Pharmaceuticals. Prior to that, Mr. Mast was a partner with Deloitte & Touche, LLP. Mr. Mast also serves on the board of directors Zogenix, Inc. Mr. Mast received a B.Sc. in business administration from California State University Bakersfield.